Canaccord Genuity Starts ZELTIQ Aesthetics (ZLTQ) at Buy; Uniquely Positioned
Get Alerts ZLTQ Hot Sheet
Price: $56.48 --0%
Rating Summary:
7 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity initiates coverage on ZELTIQ Aesthetics (NASDAQ: ZLTQ) with a Buy. PT $10.00.
Analyst, William J. Plovanic, said, "We believe Zeltiq is uniquely positioned in the aesthetics industry with a market-expanding, non-invasive treatment for fat cell removal. We believe the company’s first-to-market advantage, combined with good clinical outcomes, an easily repeatable procedure, and profitable economics for the physician office, strongly positions the therapy for physician and patient adoption."
For an analyst ratings summary and ratings history on ZELTIQ Aesthetics click here. For more ratings news on ZELTIQ Aesthetics click here.
Shares of ZELTIQ Aesthetics closed at $5.66 yesterday.
Analyst, William J. Plovanic, said, "We believe Zeltiq is uniquely positioned in the aesthetics industry with a market-expanding, non-invasive treatment for fat cell removal. We believe the company’s first-to-market advantage, combined with good clinical outcomes, an easily repeatable procedure, and profitable economics for the physician office, strongly positions the therapy for physician and patient adoption."
For an analyst ratings summary and ratings history on ZELTIQ Aesthetics click here. For more ratings news on ZELTIQ Aesthetics click here.
Shares of ZELTIQ Aesthetics closed at $5.66 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
- Canaccord Starts Galiano Gold (GAU:CN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share